Company research
Septerna, Inc.
CIK 1984086Updated Sep 24, 2026
SecuritySEPN · NASDAQ · equity
SEPN price & chart
Loading TradingView…
NASDAQ:SEPN on TradingView ↗About the company
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
In the news
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer ↗
Recent filings
4 filing
3 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 596,187,000Source | 456,554,000Source | 130,867,000Source |
| Property, Plant and Equipment, NetUSD | 4,434,000Source | 5,090,000Source | 4,665,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 120,722,000Source | 238,196,000Source | 88,483,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 10,356,000Source | 171,000Source | 151,000Source |
| Assets, CurrentUSD | 410,964,000Source | 356,824,000Source | 112,678,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 9,519,000Source | 5,730,000Source | 1,419,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,499,000Source | 23,602,000Source | 12,522,000Source |
| Other Assets, NoncurrentUSD | 816,000Source | 267,000Source | 97,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 214,261,000Source | 36,507,000Source | 20,026,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 45,000Source | 44,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -167,253,000Source | -118,374,000Source | -46,576,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 617,000Source | 56,000Source | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 381,926,000Source | 420,047,000Source | -38,374,000Source |
| Additional Paid in Capital, Common StockUSD | 548,517,000Source | 538,321,000Source | 8,199,000Source |
| Liabilities and EquityUSD | 596,187,000Source | 456,554,000Source | 130,867,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 86,931,000Source | 12,849,000Source | 6,914,000Source |
| Operating Lease, Liability, CurrentUSD | 2,212,000Source | 1,851,000Source | 0Source |
| Accounts Payable, CurrentUSD | 10,283,000Source | 3,200,000Source | 2,637,000Source |
| Operating Lease, Liability, NoncurrentUSD | 21,413,000Source | 23,625,000Source | 12,566,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 33,000Source | 546,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 12,167,000Source | 7,798,000Source | 4,277,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 491,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -48,879,000Source | -71,798,000Source | 4,180,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 1,600,000Source | 1,400,000Source | 800,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,476,000Source | 3,152,000Source | 1,620,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 10,185,000Source | 20,000Source | 151,000Source |
| Increase (Decrease) in Accounts PayableUSD | 6,603,000Source | 723,000Source | -653,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | -491,000Source | 491,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 110,189,000Source | -67,470,000Source | -38,723,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -229,352,000Source | -160,598,000Source | 22,122,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 518,000Source | 2,103,000Source | 2,878,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 1,689,000Source | 377,781,000Source | 74,520,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -117,474,000Source | 149,713,000Source | 57,919,000Source |
| Supplemental disclosure of cash flow information: | |||
| Income Taxes Paid, NetUSD | 0Source | 232,000Source | 75,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 8,476,000Source | 3,152,000Source | 1,620,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 12,500,000Source | 0Source | 47,625,000Source |
| General and Administrative ExpenseUSD | 29,164,000Source | 16,561,000Source | 9,722,000Source |
| Income Tax Expense (Benefit)USD | 12,000Source | -498,000Source | 691,000Source |
| Investment Income, InterestUSD | 19,530,000Source | 8,617,000Source | 2,786,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,879,000Source | -71,798,000Source | 4,180,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -71,798,000Source | 567,000Source |
| Nonoperating Income (Expense)USD | 19,430,000Source | 8,527,000Source | 2,796,000Source |
| Operating ExpensesUSD | 114,248,000Source | 81,898,000Source | -1,924,000Source |
| Operating Lease, ExpenseUSD | 2,103,000Source | 1,383,000Source | 807,000Source |
| Other Nonoperating Income (Expense)USD | -100,000Source | -90,000Source | 10,000Source |
| Proceeds from Stock Options ExercisedUSD | 973,000Source | 52,000Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 45,951,000Source | 1,075,000Source | 151,000Source |
| Operating Income (Loss)USD | -68,297,000Source | -80,823,000Source | 2,075,000Source |
| Other Nonoperating Income (Expense)USD | -100,000Source | -90,000Source | 10,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -48,867,000Source | -72,296,000Source | 4,871,000Source |
| Income Tax Expense (Benefit)USD | 12,000Source | -498,000Source | 691,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,879,000Source | -71,798,000Source | 4,180,000Source |
| Earnings Per Share, BasicUSD per share | -1.1Source | -7.26Source | 0.29Source |
| Earnings Per Share, DilutedUSD per share | -1.1Source | -7.26Source | 0.29Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 44,258,338Source | 9,891,126Source | 1,928,586Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 44,258,338Source | 9,891,126Source | 2,177,124Source |
| Additional Financial Items | |||
| Current Income Tax Expense (Benefit)USD | 12,000Source | -7,000Source | 200,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,604,000Source | 1,401,000Source | 848,000Source |
| General and Administrative ExpenseUSD | 29,164,000Source | 16,561,000Source | 9,722,000Source |
| Investment Income, InterestUSD | 19,530,000Source | 8,617,000Source | 2,786,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -71,798,000Source | 567,000Source |
| Nonoperating Income (Expense)USD | 19,430,000Source | 8,527,000Source | 2,796,000Source |
| Operating ExpensesUSD | 114,248,000Source | 81,898,000Source | -1,924,000Source |
| Operating Lease, ExpenseUSD | 2,103,000Source | 1,383,000Source | 807,000Source |
| Research and Development ExpenseUSD | 97,584,000Source | 65,337,000Source | 35,979,000Source |
Filing attachments
d172697dex991.htm · 8-K · 2026-08-25
EX-99.1 2 d172697dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer SOUTH SAN FRANCISCO, Calif. - August 25, 2026 - Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with …
Read attachment ↗sepn-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 sepn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif. - August 10, 2026 - Septerna, Inc. (Na…
Read attachment ↗sepn-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 sepn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism Cash Position of $522.1 Million Expected to Support Operating Plans at …
Read attachment ↗d57504dex991.htm · 8-K · 2026-04-13
EX-99.1 2 d57504dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif. - April 13, 2026 - Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pione…
Read attachment ↗d57504dex992.htm · 8-K · 2026-04-13
EX-99.2 3 d57504dex992.htm EX-99.2 EX-99.2 Pioneering a New Era of GPCR Drug Discovery April 2026 Nasdaq: SEPN Corporate Presentation Exhibit 99.2 Forward-Looking Statements This presentation contains express or implied forward‐looking statements of Septerna, Inc. (the “Company,” “we,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical facts contained in this presentation, including statements…
Read attachment ↗